NCT00317707View on ClinicalTrials.gov

Risk and Prevention Study: Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular Risk

PHASE3CompletedINTERVENTIONAL

Enrollment

12,513

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions

Cardiovascular Diseases

Interventions

DRUG

N-3 Polyunsaturated Fatty Acids

Each subject assigned to active treatment group will receive 1g/day capsule of n-3 PUFA

DRUG

Placebo: Olive oil

Each subject assigned to the control group will receive 1 g/day capsule of olive oil.

Trial Locations (1)

20156

Mario Negri Institute for Pharmacological Research, Milan

All Listed Sponsors

lead

Mario Negri Institute for Pharmacological Research

OTHER

NCT00317707 - Risk and Prevention Study: Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular Risk | Biotech Hunter | Biotech Hunter